MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Danaher Corporation Accounts Payables 2011-2026 | DHR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.84 B | 1.75 B | 1.77 B | 1.86 B | 2.57 B | 2.05 B | 1.51 B | 1.71 B | 1.51 B | 1.48 B | 1.39 B | 1.82 B | 1.78 B | 1.55 B | 1.42 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 B | 1.39 B | 1.73 B |
Quarterly Accounts Payables Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 B | 1.75 B | - | - | - | 2.42 B | 2.36 B | 2.57 B | 2.13 B | 1.97 B | 2.57 B | 2.05 B | 2.05 B | 2.05 B | 2.05 B | 1.52 B | 1.51 B | 1.51 B | 1.51 B | 1.5 B | 1.71 B | 1.71 B | 1.71 B | 1.51 B | 1.51 B | 1.51 B | 1.51 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 1.39 B | 1.39 B | 2.05 B | 2.05 B | 1.82 B | 1.82 B | 1.88 B | 1.88 B | 1.74 B | 1.78 B | 1.78 B | 1.78 B | 1.55 B | 1.55 B | 1.55 B | 1.55 B | 1.42 B | 1.42 B | 1.42 B | 1.42 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 B | 1.39 B | 1.74 B |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
165 K | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Agilent Technologies
A
|
446 M | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | USA |
 |
Celcuity
CELC
|
9.37 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
 |
Fulgent Genetics
FLGT
|
18.4 M | $ 13.82 | -2.68 % | $ 418 M | USA |
 |
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
6.9 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
149 M | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
ICON Public Limited Company
ICLR
|
173 M | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
110 M | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M |  China |
 |
Laboratory Corporation of America Holdings
LH
|
841 M | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Lantheus Holdings
LNTH
|
42.9 M | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
Mettler-Toledo International
MTD
|
267 M | $ 1 315.61 | -0.56 % | $ 27.1 B |  Schweiz |
|
Biodesix
BDSX
|
2.19 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Myriad Genetics
MYGN
|
30 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
23.1 M | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
1.3 M | $ 13.37 | -3.47 % | $ 328 M | USA |
 |
Natera
NTRA
|
31.1 M | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
14 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
6.96 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
307 M | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Organovo Holdings
ONVO
|
1.64 M | - | -2.3 % | $ 19.4 M | USA |
 |
OPKO Health
OPK
|
47.1 M | $ 1.22 | -2.02 % | $ 847 M | USA |
 |
Pacific Biosciences of California
PACB
|
20.8 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Exact Sciences Corporation
EXAS
|
176 M | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
23 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
1.13 M | $ 10.3 | -4.19 % | $ 292 M |  Israel |
 |
DexCom
DXCM
|
344 M | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
185 M | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
752 K | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
622 K | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
4.66 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
221 M | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
Renalytix AI plc
RNLX
|
1.4 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
VolitionRx Limited
VNRX
|
2.77 M | $ 0.2 | -0.74 % | $ 19.2 M |  Singapore |